Is miRNA being used in clinical oncology today beyond OncuraKit?

Yes. MiRNA is actively used and studied in clinical oncology beyond early detection. miR-21 levels in tumor tissue are used in some centers as a prognostic marker for colorectal cancer — high miR-21 expression correlates with worse outcomes. miR-155 overexpression is associated with chemotherapy resistance in breast cancer. Several clinical trials are investigating miRNA mimics and inhibitors (antagomirs) as therapeutic agents for various cancers. In diagnostics, miRNA expression profiling of biopsied tissue is used to classify tumors of unknown primary origin. OncuraKit represents the leading edge of non-invasive, early-detection miRNA applications — taking this established molecular knowledge and applying it pre-symptomatically, before a diagnosis has been made.